HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Human pancreatic tumor growth hormone-releasing factor: dose-response relationships in normal man.

Abstract
Human pancreatic GRF (hpGRF-40; 1 microgram/kg, iv) selectively stimulates GH release in normal men (9). We now report the effects of graded doses of hpGRF-40 on GH release in 12 normal men. Mean peak increments in serum GH after vehicle and the various doses of hpGRF-40 were 1.13, 11.40, 14.60, 17.01, 14.45, and 15.60 ng/ml after vehicle and 0.1, 0.33, 1.0, 3.3, and 10 micrograms/kg hpGRF-40 (iv bolus), respectively. Peak values were observed 30-60 min after hpGRF-40 treatment. There was considerable variability of responsiveness among individual subjects, and no dose-response relationship between the doses and maximal GH values was found. However, the higher doses of 3.3 and 10.0 micrograms/kg resulted in a more prolonged and biphasic pattern of GH release. A side effect of facial flushing of less than 5-min duration occurred in 4 or 6 subjects who received 3.3 micrograms/kg and in all 5 who received 10 micrograms/kg of hpGRF-40. No changes in serum glucose, LH, TSH, PRL, plasma cortisol, or 8 enteropancreatic hormones occurred after hpGRF-40 treatment. There were small increases in serum somatomedin C levels 24 h after the administration of various doses of hpGRF-40 in 11 of 13 studies. Plasma immunoreactive GRF levels measured 5 min after injection were 0.09, 2.0, 4.9, 23.9, and 66.6 ng/ml after 0.1, 0.33, 1.0, 3.3, and 10 micrograms/kg hpGRF-40, respectively. Serum GH responses after insulin-induced hypoglycemia were compared to GH responses after hpGRF-40. Comparable peak GH stimulation occurred with both provocative tests. Mean +/- SEM peak GH was 20.2 +/- 1.0 ng/ml after insulin and 20.9 +/- 3.2 after hpGRF-40 treatment. hpGRF-40 selectively stimulates GH release in normal men over a dose range of 0.1-10 micrograms/kg and is an effective probe to investigate the dynamics of GH release.
AuthorsM L Vance, J L Borges, D L Kaiser, W S Evans, R Furlanetto, J L Thominet, L A Frohman, A D Rogol, R M MacLeod, S Bloom
JournalThe Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 58 Issue 5 Pg. 838-44 (May 1984) ISSN: 0021-972X [Print] United States
PMID6423660 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Blood Glucose
  • Gastrointestinal Hormones
  • Insulin
  • Pancreatic Hormones
  • Prolactin
  • Luteinizing Hormone
  • Thyrotropin
  • Growth Hormone
  • Growth Hormone-Releasing Hormone
  • Hydrocortisone
Topics
  • Adult
  • Blood Glucose (metabolism)
  • Dose-Response Relationship, Drug
  • Gastrointestinal Hormones (blood)
  • Growth Hormone (blood)
  • Growth Hormone-Releasing Hormone (pharmacology)
  • Humans
  • Hydrocortisone (blood)
  • Insulin (pharmacology)
  • Luteinizing Hormone (blood)
  • Male
  • Pancreatic Hormones (blood)
  • Prolactin (blood)
  • Thyrotropin (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: